Saracino Medical Limited 14268574 false 2022-08-01 2023-12-31 2023-12-31 The principal activity of the company is Specialists medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true 14268574 2022-08-01 2023-12-31 14268574 2023-12-31 14268574 bus:OrdinaryShareClass1 2023-12-31 14268574 bus:OrdinaryShareClass2 2023-12-31 14268574 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 14268574 bus:SmallEntities 2022-08-01 2023-12-31 14268574 bus:AuditExemptWithAccountantsReport 2022-08-01 2023-12-31 14268574 bus:FilletedAccounts 2022-08-01 2023-12-31 14268574 bus:SmallCompaniesRegimeForAccounts 2022-08-01 2023-12-31 14268574 bus:RegisteredOffice 2022-08-01 2023-12-31 14268574 bus:Director1 2022-08-01 2023-12-31 14268574 bus:OrdinaryShareClass1 2022-08-01 2023-12-31 14268574 bus:OrdinaryShareClass2 2022-08-01 2023-12-31 14268574 bus:PrivateLimitedCompanyLtd 2022-08-01 2023-12-31 14268574 countries:England 2022-08-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 14268574

Saracino Medical Limited

Unaudited Filleted Abridged Financial Statements

for the Period from 1 August 2022 to 31 December 2023

 

Saracino Medical Limited

Contents

Company Information

1

Abridged Balance Sheet

2

Notes to the Unaudited Abridged Financial Statements

3 to 4

 

Saracino Medical Limited

Company Information

Director

Andrea Saracino

Registered office

Anglo House
Worcester Road
Stourport on Severn
DY13 9AW

Accountants

Perrigo Consultants Limited
Anglo House
Worcester Road
Stourport on Severn
DY13 9AW

 

Saracino Medical Limited

(Registration number: 14268574)
Abridged Balance Sheet as at 31 December 2023

Note

2023
£

Current assets

 

Cash at bank and in hand

 

6,725

Creditors: Amounts falling due within one year

(2,068)

Total assets less current liabilities

 

4,657

Accruals and deferred income

 

(986)

Net assets

 

3,671

Capital and reserves

 

Called up share capital

5

110

Retained earnings

3,561

Shareholders' funds

 

3,671

For the financial period ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 30 July 2024
 

.........................................
Andrea Saracino
Director

 

Saracino Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Period from 1 August 2022 to 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Anglo House
Worcester Road
Stourport on Severn
DY13 9AW

These financial statements were authorised for issue by the director on 30 July 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

3

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 1.

 

Saracino Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Period from 1 August 2022 to 31 December 2023

4

Debtors

Debtors includes £Nil due after more than one year.

5

Share capital

Allotted, called up and fully paid shares

2023

No.

£

A of £1 each

100

100

B of £1 each

10

10

110

110